|
|
| (9 intermediate revisions not shown) |
| Line 1: |
Line 1: |
| | {{:Team:British Columbia/Templates/MainHeader}} | | {{:Team:British Columbia/Templates/MainHeader}} |
| | <html> | | <html> |
| - | <div class="container">
| |
| - | <div class="page-header">
| |
| - | <h1>Achievements</h1>
| |
| | <style> | | <style> |
| | .a,.g,.s,.b { | | .a,.g,.s,.b { |
| Line 52: |
Line 49: |
| | } | | } |
| | </style> | | </style> |
| - | </html>
| |
| | | | |
| | + | <div class="container"> |
| | + | <div class="page-header"> |
| | + | <h1>Achievements</h1> |
| | | | |
| | <br> | | <br> |
| - | <html>
| |
| - | <a name="top"></a>
| |
| | <center> | | <center> |
| - | <img src="https://static.igem.org/mediawiki/2013/9/9c/UBCigemGOLD.jpg" width="650"> | + | <div style="height: 300px; width: 600px; float: center"> |
| - | </center>
| + | |
| - | <br>
| + | |
| | | | |
| - | <br> | + | <div id="medals"> |
| | | | |
| - | <p>
| |
| - | <center><div style="height: 300px; width: 600px; float: center">
| |
| - |
| |
| - | <ul class="a">
| |
| - |
| |
| - |
| |
| - |
| |
| - | =='''Medal requirements'''==
| |
| - | <html>
| |
| - |
| |
| - | <div id="medals">
| |
| | <ul class="b"> | | <ul class="b"> |
| - | <li>Submitted 40 and characterized 25 new <a href="https://2013.igem.org/Team:British_Columbia/Parts">biobrick parts</a></li> | + | <li> Submitted 12 new biobricks </li> |
| | </ul> | | </ul> |
| | | | |
| | <ul class="s"> | | <ul class="s"> |
| - | <li>Submitted Cas9 (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1129006">BBa_K1129006</a>) as our favorite functional part and showed evidence of immunity against phage using CRISPR components. </li> | + | <li> Demonstrated an activity with two of the biobricks </li> |
| - | <li>Obtained <a href="https://2013.igem.org/Team:British_Columbia/humanpractices/EthicsApproval">ethics approval</a> to <a href="https://2013.igem.org/Team:British_Columbia/humanpractices/ConductSurvey"> survey public’s perception</a> of GMOs with the aim to create a <a href="https://2013.igem.org/Team:British_Columbia/marketing">marketing strategy for a GM Yogurt</a>, following <a href="https://2013.igem.org/Team:British_Columbia/humanpractices/Interviews">interviews</a> with dairy industry and academic professionals </li> | + | <li> In testing the biobricks, discovered that a native membrane component in ''Caulobacter'' bounded minerals </li> |
| | </ul> | | </ul> |
| | | | |
| | <ul class="g"> | | <ul class="g"> |
| - | <li>Improved 3 existing caffeine biosynthesis biobricks (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1129013"> BBa_K1129013 </a>, <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1129015"> BBa_K1129015</a>, <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1129017"> BBa_K1129017</a>) from TU Munich 2012 by replacing a yeast consensus sequence with a bacterial ribosome-binding site for prokaryotic engineering</li> | + | <li> Assessed commercialization feasibility from a regulatory, economic and integration perspective </li> |
| - | <li>Characterized previous iGEM parts (from <a href="https://2012.igem.org/Team:LMU-Munich"> TU Munich 2012</a>, <a href="https://2009.igem.org/Team:KULeuven/Project">KU Leuven 2009</a>, <a href="https://2007.igem.org/Edinburgh">Edinburgh 2007</a>) in <a href="https://2013.igem.org/Team:British_Columbia/Project/Vanillin">vanillin</a>, <a href="https://2013.igem.org/Team:British_Columbia/Project/Cinnamaldehyde">cinnamaldehyde</a> and <a href="https://2013.igem.org/Team:British_Columbia/Project/Caffeine">caffeine</a> biosynthesis pathways and were able to show functional data for substrate conversion. We are the only team to show data for <a href="https://2013.igem.org/Team:British_Columbia/Project/Vanillin#Data">vanillin</a> and <a href="https://2013.igem.org/Team:British_Columbia/Project/Cinnamaldehyde#Characterization">cinnamaldehyde</a> production in E. coli!</li>
| + | </ul> |
| - | <li>Currently exploring the consequences of off-target activity in the CRISPR system. We are in the process of developing a resource (<a href="https://2013.igem.org/Team:British_Columbia/humanpractices/SpaceR">SPACE-R</a>) to assess the safety and specificity of individual spacer sequences.</li> | + | |
| - | <li>Developed <a href="https://2013.igem.org/Team:British_Columbia/Modeling">comprehensive models</a> that (1) predict growth of CRISPR-expressing E. coli cultures under phage predation, visualized using ‘Gro simulation’ (2) compute the cinnamaldehyde production following population tuning with various initial starting number of viruses</li>
| + | |
| | | | |
| | </div> | | </div> |
| - | </html>
| |
| | | | |
| | + | </div> |
| | + | |
| | + | </div> |
| | + | |
| | + | </div> |
| | | | |
| - | <html>
| |
| - | <div align="right"><a href="#top">Top of Page</a></div>
| |
| | </html> | | </html> |
"
